damage specific DNA binding protein 2Genealiases: DDBB · UV-DDB2 · XPE
Q-omics provides the consensus-scored DDB2 profile across patient tissues and cancer cell-line models. DDB2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DDB2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DDB2 protein abundance shows 23,879 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, KIRC, and LUAD as cancer lineages where DDB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDB2 survival associations across molecular data types. DDB2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDB2 RNA expression–survival associations across cancer types. High DDB2 expression shows unfavorable associations in LGG and KICH, but favorable associations in KIRP, UCEC, BRCA and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DDB2 RNA expression.
This table summarizes DDB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DDB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDB2 shows lower tumor expression in BRCA and higher tumor expression in KIRC, KIRP, THCA, COAD and LIHC. The KIRC box plot shows higher DDB2 RNA expression in tumor versus normal tissue (log2 FC = +1.942, t-test p < 0.001).
This table shows molecular features associated with DDB2 in patient tissues and cancer cell lines. In patient samples, DDB2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DDB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
